CureVac NV Receives Positive Patent Decision from European Patent Office

CureVac NV, a clinical-stage biopharmaceutical company based in Tübingen, Germany, has received another favorable decision regarding the validity of its patents from the European Patent Office (EPO). This decision comes amid ongoing litigation with BioNTech SE, a prominent player in the biotechnology sector.

Patent Validity Upheld

On May 15, 2025, the EPO largely dismissed the opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023. The opposition challenged the validity of European Patent EP 4 023 755 B1. The EPO has maintained the patent, subject to amendments to specific claims. Additionally, a hearing on the infringement of EP 4 023 755 B1 will also include EP 3 708 668 B1, whose validity was confirmed in an amended form.

Market Reaction

CureVac’s shares, listed on the Frankfurt Stock Exchange, closed at 3.07 EUR on May 14, 2025. The company’s market capitalization stands at approximately 702 million EUR. The recent patent decision could potentially influence investor sentiment and the company’s stock performance, given the ongoing legal dispute with BioNTech SE.

Company Overview

CureVac specializes in developing transformative medicines based on messenger ribonucleic acid (mRNA), aiming to improve patient outcomes globally. The company operates worldwide and is listed on the Frankfurt Stock Exchange.

Conclusion

The positive decision from the EPO marks a significant development in CureVac’s legal battle with BioNTech SE. As the case progresses, further updates may impact the company’s strategic positioning and market valuation.